Dilek BERKER, Özden ÖZDEMİR BAŞER, Salih Suha KOPARAL, Derya KÖSEOĞLU

Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study

Background/aim: The aim of this study was to evaluate the effects of a 6-month treatment regimen with exenatide on the lipid profile, high-sensitivity C-reactive protein (hsCRP), carotid intima media thickness (CIMT), visceral adiposity, and nonalcoholic fatty liver disease (NAFLD), all of which are important cardiovascular risk factors. Materials and methods: This study included 45 obese patients with type 2 diabetes mellitus (T2DM). Baseline clinical findings, laboratory parameters, and ultrasonography findings were recorded. An exenatide recipe was given twice daily to the patients and, after 6 months of therapy, the same variables were compared. The compared parameters were lipid profiles, hsCRP, aspartat aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, liver craniocaudal diameter, visceral fat volume, subcutaneous fat thickness, and CIMT. Liver diameter, visceral fat volume, subcutaneous fat thickness, and CIMT were measured by ultrasonography. Results: After therapy, statistically significant improvements were achieved in lipid profile, hsCRP, liver enzymes, body mass index, and waist and hip circumferences. Also, statistically significant decreases were obtained in liver craniocaudal diameter, subcutaneous fat thickness, visceral fat volume, and CIMT. The reduction of CIMT and liver diameter were not correlated with BMI and HbA1c reduction. Conclusion: This study showed improvement in lipid profile and hsCRP levels with exenatide treatment. We also showed decrease in both visceral fat volume and subcutaneous fat thickness. We demonstrated significant decrease in liver enzymes with significant decrease in liver diameter. These findings support the use of exenatide in patients with NAFLD and T2DM. Additionally, this study showed that exenatide treatment given twice daily reduces CIMT in obese T2DM patients.Key words: Carotid intima media thickness, hsCRP, nonalcoholic fatty liver disease, subcutaneous fat thickness, visceral fat volume, lipid profile

PDF

___

1. Hu G, Jousilahti P, Qiao Q, Katoh S, Tuomilehto J. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia 2005; 48 (5):856-861. doi: 10.1007/s00125-005-1730-6
2. Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Clevel and Clinic Journal of Medicine 2009; 76 Suppl 5: S4-11. doi: 10.3949/ccjm.76. s5.02
3. Astrup A, Finer N. Redefining type 2 diabetes: ‘diabesity’ or ‘obesity dependent diabetes mellitus’? Obesity Reviews 2000; 1 (2): 57-59. doi: 10.1046/j.1467-789x.2000.00013.x
4. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66 (6): 1138-1153. doi: 10.1136/gutjnl-2017-313884
5. Le Jemtel TH, Samson R, Milligan G, Jaiswal A, Oparil S. Visceral adipose tissue accumulation and residual cardiovascular risk. Current Hypertension Reports 2018; 20 (9): 77. doi: 10.1007/s11906-018-0880-0
6. Yoo BK, Triller DM, Yoo DJ. Exenatide: a new option for the treatment of type 2 diabetes. The Annals of Pharmacotherapy 2006; 40 (10): 1777-1784. doi: 10.1345/aph.1H060
7. Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. The Journal of Clinical Endocrinolology and Metabolism 2015; 100 (2): 363-370. doi: 10.1210/jc.2014-3421
8. Fan H, Pan Q, Xu Y, Yang X. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arquivos Brasil eirosde Endocrinologiae Metabologia 2013; 57 (9): 702- 708. doi:10.1590/s0004-27302013000900005
9. Du X, Lu W, Lu Z, Shao X, Hu C et al. Exenatide with Metformin ameliorated visceral adiposity and insulin resistance. Journal of Diabetes Research 2018; 2018: 4019248. doi: 10.1155/2018/4019248
10. Shao N, Kuang HY, Hao M, Gao XY, Lin WJ et al. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metabolism Research and Reviews 2014; 30 (6): 521- 529.doi: 10.1002/dmrr.2561
11. Simó R, Guerci B, Schernthaner G, Gallwitz B, Rosas-Guzmàn J et al. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily orglimepiride: results from the European exenatide study. Cardiovascular Diabetology 2015; 14 :116. doi: 10.1186/s12933-015-0279-z
12. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. The New England Journal of Medicine 1999; 340 (1): 14-22. doi:10.1056/NEJM199901073400103
13. Lim S, Lee GY, Park HS, Lee DH, TaeJung Oet al. Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats. Cardiovascular Research 2017; 113 (2): 183-194. doi: 10.1093/cvr/cvw213
14. Patti AM, Nikolic D, Magan-Fernandez A, Giglio RV, Castellino G et al. Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: an 8-month prospective study. Diabetes Research and Clinical Practice 2019; 149: 163-169. doi: 10.1016/j.diabres.2019.02.006
15. Mazidi M, Karimi E, Rezaie P, Ferns GA. Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and metaanalysis of randomized controlled trials. Journal of Diabetes and its Complications 2017; 31 (7): 1237-1242. doi: 10.1016/j. jdiacomp.2016.05.022
16. Hirooka M, Kumagi T, Kurose K, Nakanishi S, Michitaka Ket al. A technique for the measurement of visceral fat by ultrasonography: comparison of measurements by ultrasonography and computed tomography. Internal Medicine 2005; 44 (8): 794-799. doi:10.2169/internalmedicine.44.794
17. Buse JB, Henry RR, Han J, Kim DD, Fineman MS et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 2 7 (11): 2628-2635. doi: 10.2337/diacare.27.11.2628
18. Nikfar S, Abdollahi M, Salari P. The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials. Journal of Pharmacy & Pharmaceutical Sciences 2012; 15 (1): 1-30. doi:10.18433/j3g883
19. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptoragonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344: d7771. doi: 10.1136/bmj. d7771
20. Taylor G. Science to practice: good fat, bad fat–does location matter? Radiology 2007; 242 (3): 645-646. doi: 10.1148/ radiol.2423061562
21. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Digestive Diseases and Sciences 2005; 50 (1): 171-180. doi: 10.1007/s10620-005-1267-z
22. Sinn DH, Kang D, Chang Y, Ryu S, Cho SJ et al. Non-alcoholic fatty liver disease and the incidence of myocardial infarction: a cohort study. Journal of Gastroenterology and Hepatolology 2020; 35 (5): 833-839. doi: 10.1111/jgh.14856
23. Baratta F, Pastori D, Angelico F, Balla A, Paganini A M et al. Non alcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clinical Gastroenterology and Hepatology 2020; 18 (10): 2324- 2331. doi: 10.1016/j.cgh.2019.12.026
24. Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World Journal of Gastroenterology 2017; 23 (36): 6549-6570. doi: 10.3748/wjg.v23.i36.6549
25. Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet Bet al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study. The Journal of Clinical Endocrinology and Metabolism 2017; 102 (2): 407-415. doi: 10.1210/jc.2016-2775
26. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D et al. Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387 (10019): 679-690. doi: 10.1016/S0140-6736(15)00803-X
27. Papatheodoridi M, Cholongitas E. Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts. Current Pharmaceutical Design 2018; 24 (38): 4574-4586. doi: 10.217 4/1381612825666190117102111
28. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54 (3): 1082-1090. doi: 10.1002/hep.24452
29. Li S, Wang X, Zhang J, Li J, Liu Xet al. Exenatid eameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease. Brazilian Journal of Medical and Biological Research 2018; 51 (8): e7299. doi: 10.1590/1414-431x20187299
30. Cardoso CRL, Salles GC, Leite NC, Salles GF. Prognostic impact of carotid intima-media thickness and carotid plaques on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovascular Diabetology 2019; 18 (1): 2. doi: 10.1186/s12933-019-0809-1
31. Zhang J, Xian TZ, Wu MX, Li C, Pan Q et al. Comparison of the effects of twice-daily exenatide and insulin on carotid intimamedia thickness in type 2 diabetes mellitus patients: a 52- week randomized, open-label, controlled trial. Cardiovascular Diabetology 2020; 19 (1): 48. doi: 10.1186/s12933-020-01014-7
32. Wang Y, Ma X, Zhou M, Zong W, Zhang Let al. Contribution of visceral fat accumulation to carotid intima-media thickness in a Chinese population. International Journal of Obesity (Lond) 2012; 36 (9): 1203-1208. doi: 10.1038/ijo.2011.222
33. Kotsis VT, Stabouli SV, Papamichael CM, Zakopoulos NA. Impact of obesity in intimamedia thickness of carotidarteries. Obesity (Silver Spring) 2006; 14 (10): 1708-1715. doi: 10.1038/ oby.2006.196
34. Bułdak Ł, Łabuzek K, Bułdak RJ, Machnik G, Bołdys A et al. Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages. Naunyn Schmiedebergs Arch Pharmacol 2015; 388 (9): 905- 919. doi: 10.1007/s00210-015-1124-3
35. Scalzo RL, Moreau KL, Ozemek C, Herlache L, McMillin S et al. Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes. Journal of Diabetes and its Complications 2017; 31 (2): 449-455.d oi: 10.1016/j.jdiacomp.2016.10.003